Skip to main content

Hereditary Spastic Paraplegia

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Gloria Biosciences
Gloria BiosciencesChina - Guangzhou
1 program
C-mill interventionN/A1 trial
Active Trials
NCT04180098Completed36Est. Apr 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Gloria BiosciencesC-mill intervention

Clinical Trials (1)

Total enrollment: 36 patients across 1 trials

Improving Gait Adaptability in Hereditary Spastic Paraplegia

Start: Dec 2019Est. completion: Apr 202236 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.